Table 1 Summary of 5-FU and oxaliplatin-based therapy as second-line therapy
Treatment | Author/year | N | Weighted PS | Original PS | Prior surgery (%) | Deaths | Median OS (m) | ORR (%) |
|---|---|---|---|---|---|---|---|---|
OFF | Pelzer 2009 [28] | 37 | 1.5 | KS: Median: 70, range: [60, 90] | 43 | 33 | 5.1 | 6 |
OFF | Pelzer 2011 [27] | 23 | 1.3 | KS: Median: 80, range: [70, 100] | NR | 18 | 4.8 | 0 |
OFF | Oettle 2014 [14] | 76 | 1.2 | KS: (90–100) (53.9%), 70–80 (46.1%) | 45 | 73 | 5.9 | 17 |
5-FU/OXA-based | Tsavaris 2005 [29] | 30 | 1.7 | KS: (80–100) (33.4%), 70–50 (66.7%) | NR | 20 | 5.7 | 23 |
FOLFOX | Gebbia 2007 [30] | 42 | 1.4 | ECOG: 1 (62%), 2 (38%) | 9 | 38 | 6.7 | 14 |
FOLFOX | Yoo 2009 [31] | 30 | 1.0 | ECOG: 0–1 (97%) | 32 | 25 | 3.8 | 7 |
FOLFOX | Zaanan 2014 [24] | 12 | 1.0 | ECOG: 0–1 (100%) | 0 | 10 | 5.9 | 0 |
FOLFOX | Zaanan 2014 [24] | 12 | 2.5 | ECOG: 2–3 (100%) | 0 | 12 | 2.6 | 0 |
FOLFOX | Gill 2016 [16] | 54 | 1.1 | ECOG: 0–1 (89%), 2 (11%) | NR | 47 | 6.1 | 13 |
FOLFOX | Berk 2012 [32] | 46 | 1.2 | ECOG: 0–1 (78%), 2 (22%) | NR | 33.6 | 6.2 | 17 |
OFF | El-Hadaad 2013 [33] | 30 | 1.2 | ECOG: 0–1 (83.4%), 2 (16%) | NR | 29 | 5.1 | 7 |
FOLFOX | Chung 2017 [15] | 62 | 1.0 | ECOG: 0–1 (100%) | NR | 53 | 6.7 | 11 |